Pricing Log in Create free account

Kyverna Therapeutics, Inc. (KYTX) vs Prelude Therapeutics Incorporated (PRLD)

Kyverna Therapeutics, Inc. and Prelude Therapeutics Incorporated are both Biotechnology companies. Kyverna Therapeutics, Inc. and Prelude Therapeutics Incorporated are of similar size ($285.1M and $283.7M). Kyverna Therapeutics, Inc. has the higher net margin (0.00% vs −269.8%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Prelude Therapeutics Incorporated leads on 7 and Kyverna Therapeutics, Inc. on 5.

Valuation

Metric KYTX PRLD Biotechnology median
P/E n/m n/m 10.60
P/S n/m 15.80 9.40
P/B 1.78 2.65 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 9.03 9.02
Earnings yield (60.62%) (20.28%) (32.88%)
Free cash flow yield (53.83%) (9.41%) (23.13%)

Profitability

Metric KYTX PRLD Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin 0.00% (300.56%) 0.00%
Net margin 0.00% (269.75%) 0.00%
Free cash flow margin 0.00% (148.30%) 0.00%
Return on equity (87.24%) (57.73%) (51.96%)
Return on assets (68.40%) (39.76%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KYTX PRLD Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (9.31%) 23.21% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KYTX PRLD Biotechnology median
Debt to equity 0.15 0.00 0.00
Current ratio 9.06 4.07 4.97
Net debt to EBITDA 1.51 1.00 1.01

Dividend

Metric KYTX PRLD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KYTX PRLD Biotechnology median
Market cap 285.10m 283.70m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack